X
AbbVie braces for impact of Humira biosimilars in Europe
https://pharmaphorum.com/news/abbvie-braces-for-impact-of-humira-biosimilars-in-europe/
Humira
Payday for AbbVie as Humira biosimilar delayed for five years
Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
AbbVie bullish on Humira and near-term pipeline
Sales of Humira could peak above $18 billion – CEO
Amjevita, first Humira biosimilar approved – but no launch yet
Amgen’s biosimilar is ready to go, but AbbVie believes it can delay until 2022
AbbVie waits on data from Humira successor
Ablynx’s vobarilizumab seen as key should Humira sales fall.
FDA advisers back Amgen’s Humira biosimilar
ABP 501 gets backing from FDA panel.
Biogen eyeing big-selling biosimilars as MS drug fails
Gamble on opicinumab looks unlikely to pay off.
1 2
